An Official Website of the United States Government
Novel approaches to extending glucose sensor lifespan
- Small Business Information
-
AEGIS BIOSCIENCES, LLCAEGIS BIOSCIENCES, LLC 665 N. RIVERPOINT BLVD SPOKANE, WA 99202View profile »Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2009Title: Novel approaches to extending glucose sensor lifespanAgency: HHSContract: 1R43DK085957-01Award Amount: $844,788.00
Abstract:
DESCRIPTION (provided by applicant): Long term transcutaneous devices such as catheters; require patients to endure extended skin breaches (wounds) that can be difficult to manage clinically, i.e. infection and inflammation. These complications not only sh orten device lifespan, but also compromise patient health. In the case of short-term commercial transcutaneous glucose sensors, FDA has approved their usage for 3-7 days for patients with diabetes. Although infection is an issue with these short-term senso rs extending the in vivo lifespan of these sensors from days to weeks increases the risks of adverse effects. Adverse effects seen at sites of glucose sensor implantation include infection, irritation, redness, itching and inflammation. All these adverse e ffects can and do shorten sensor lifespan in vivo. All these adverse effectives not only compromise sensor function, but also discourage patient involvement in implantable sensors. Clearly, decreasing the risk of infections and inflammation at sensor impla ntation sites would likely not only increase sensor lifespan, but also decrease associated complications and adverse events. In the present proposal we proposed to develop and validate a number of hydrogel based sensor collars and coatings including one th at are bio-enhanced to promote sensor lifespan in vivo. These sensor collars and coatings will be used alone and in combination to extend glucose sensor function in vivo. We believe this approach will usher in a new generation of devices / adjuvants that w ill enhance the function and extend lifespan of not only existing commercial sensors, but also future generation of trancutaneous glucose sensors. PUBLIC HEALTH RELEVANCE: Increasing the implantation time frame beyond the FDA approved 3-7 days for t ranscutaneous glucose sensors increases the risk of adverse effects, such as infection, irritation, redness, itching and inflammation, at sites of sensor implantation and as such decreases sensor lifespan in vivo. In order to avoid these adverse effects we propose to develop and validate a number of hydrogel based sensor collars and coatings including one that are bio-enhanced to promote sensor lifespan in vivo.Small Business Information at Submission:AEGIS BIOSCIENCES, LLC
AEGIS BIOSCIENCES, LLC 665 N. RIVERPOINT BLVD SPOKANE, WA 99202EIN/Tax ID: 621635896DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 93738 |
Program Year/Program: 2009 / SBIR |
|
Agency Tracking Number: DK085957 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |